Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Srikripa Devarakonda is an analyst at Truist Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/28/2024
Buy Now | Get Alert | ||||||||
---|---|---|---|---|---|---|---|---|---|
06/25/2024 | LLY | Buy Now | Eli Lilly and Co | $906.04 | 10.37% | $892 → $1000 | Reiterates | Buy → Buy | Get Alert |
06/18/2024 | KROS | Buy Now | Keros Therapeutics | $45.96 | 117.58% | $100 → $100 | Maintains | Buy | Get Alert |
05/29/2024 | CYTK | Buy Now | Cytokinetics | $54.18 | 29.2% | $86 → $70 | Maintains | Buy | Get Alert |
05/01/2024 | INCY | Buy Now | Incyte | $60.62 | 36.92% | $84 → $83 | Reiterates | Buy → Buy | Get Alert |
05/01/2024 | LLY | Buy Now | Eli Lilly and Co | $906.04 | -1.55% | $850 → $892 | Maintains | Buy | Get Alert |
04/17/2024 | EWTX | Buy Now | Edgewise Therapeutics | $18.05 | 38.5% | $25 → $25 | Maintains | Buy | Get Alert |
04/08/2024 | CYTK | Buy Now | Cytokinetics | $54.18 | 58.73% | $86 → $86 | Reiterates | Buy → Buy | Get Alert |
04/03/2024 | SRRK | Buy Now | Scholar Rock Holding | $8.20 | 143.9% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
03/25/2024 | SRRK | Buy Now | Scholar Rock Holding | $8.20 | 143.9% | → $20 | Reiterates | Buy → Buy | Get Alert |
03/13/2024 | KROS | Buy Now | Keros Therapeutics | $45.96 | 117.58% | → $100 | Reiterates | Buy → Buy | Get Alert |
03/01/2024 | KYMR | Buy Now | Kymera Therapeutics | $29.85 | 80.9% | $41 → $54 | Maintains | Buy | Get Alert |
02/14/2024 | INCY | Buy Now | Incyte | $60.62 | 38.57% | $91 → $84 | Maintains | Buy | Get Alert |
12/28/2023 | CYTK | Buy Now | Cytokinetics | $54.18 | 58.73% | $60 → $86 | Maintains | Buy | Get Alert |
11/29/2023 | INCY | Buy Now | Incyte | $60.62 | 50.12% | → $91 | Reiterates | Buy → Buy | Get Alert |
11/15/2023 | VSTM | Buy Now | Verastem | $2.99 | 1037.12% | $39 → $34 | Maintains | Buy | Get Alert |
09/21/2023 | INCY | Buy Now | Incyte | $60.62 | 50.12% | → $91 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | AFMD | Buy Now | Affimed | $5.56 | 7.91% | $80 → $60 | Maintains | Buy | Get Alert |
08/02/2023 | INCY | Buy Now | Incyte | $60.62 | 50.12% | $100 → $91 | Maintains | Buy | Get Alert |
07/11/2023 | VSTM | Buy Now | Verastem | $2.99 | 1204.35% | $60 → $39 | Maintains | Buy | Get Alert |
06/30/2023 | KYMR | Buy Now | Kymera Therapeutics | $29.85 | 67.5% | → $50 | Initiates | → Buy | Get Alert |
06/28/2023 | EWTX | Buy Now | Edgewise Therapeutics | $18.05 | 38.5% | → $25 | Reiterates | Buy → Buy | Get Alert |
06/27/2023 | VSTM | Buy Now | Verastem | $2.99 | 1906.69% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
06/27/2023 | EWTX | Buy Now | Edgewise Therapeutics | $18.05 | 38.5% | → $25 | Reiterates | Buy → Buy | Get Alert |
06/23/2023 | VSTM | Buy Now | Verastem | $2.99 | 1906.69% | → $60 | Reiterates | Buy → Buy | Get Alert |
05/01/2023 | EWTX | Buy Now | Edgewise Therapeutics | $18.05 | 38.5% | → $25 | Initiates | → Buy | Get Alert |
03/20/2023 | NMTR | Buy Now | 9 Meters Biopharma | — | — | → $38 | Downgrade | Buy → Hold | Get Alert |
02/16/2023 | INCY | Buy Now | Incyte | $60.62 | 64.96% | $95 → $100 | Maintains | Buy | Get Alert |
12/20/2022 | CYTK | Buy Now | Cytokinetics | $54.18 | 10.74% | → $60 | Initiates | → Buy | Get Alert |
10/18/2022 | KROS | Buy Now | Keros Therapeutics | $45.96 | 117.58% | → $100 | Initiates | → Buy | Get Alert |
07/12/2022 | SRRK | Buy Now | Scholar Rock Holding | $8.20 | 143.9% | → $20 | Initiates | → Buy | Get Alert |
06/22/2022 | NMTR | Buy Now | 9 Meters Biopharma | — | — | $100 → $40 | Maintains | Buy | Get Alert |
03/09/2022 | VSTM | Buy Now | Verastem | $2.99 | 100.67% | → $72 | Initiates | → Buy | Get Alert |
10/21/2021 | AFMD | Buy Now | Affimed | $5.56 | 79.86% | → $100 | Initiates | → Buy | Get Alert |